Targeted Oncology2h
Tislelizumab Scores FDA Approval in Advanced Gastric and GEJ Cancers
The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...
Targeted Oncology20h
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
The FDA has approved the subcutaneous formulation of nivolumab (Opdivo). This approval makes it the first and only ...
Targeted Oncology20h
Managing Intermediate-Risk Myelofibrosis With Ruxolitinib
During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate ...